נכסים נקיים למניה בודדת VistaGen Therapeutics Inc (VTGN)

Vistagen Therapeutics (VTGN) is implementing AI modules and robotic screening for test analysis. The book value per share reflects the net asset trend, with the indicator currently standing at 0.55. Bioinformatics automation accelerates drug discovery by minimizing manual labor. Since demand for neuropsychiatric drugs remains stable regardless of GDP, business success depends on the results of clinical trials.

Vistagen Therapeutics stability is based on the capitalization of intellectual assets created in partnership with psychiatric centers to develop neuroactive agents. The current book value per share of 0.55 reflects the remaining net assets after deducting all liabilities, allowing the investor to assess the intrinsic value of the business and compare actual capital with the market price of the security.